mycophenolate mofetil (CellCept) (cont.)

Pharmacy Author:
Medical and Pharmacy Editor:

Probenecid may cause an increase in MPA blood levels by inhibiting its excretion via renal tubular secretion.

PREGNANCY: Mycophenolate mofetil is classified as FDA pregnancy risk category D. Use of mycophenolate mofetil during pregnancy is associated with increased risk of first trimester pregnancy loss and congenital malformation and is not recommended during pregnancy.

NURSING MOTHERS: Mycophenolate mofetil is excreted in milk of rats. It is not known if it also is excreted in human milk. Due to the lack of conclusive safety data, mycophenolate mofetil should be used cautiously in nursing mothers.

REFERENCE: FDA Prescribing Information.


Medically Reviewed by a Doctor on 6/2/2015


Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.


Back to Medications Index